Diabetes

Biosimilar Insulin Glargine Shows Pharmacokinetic and Pharmacodynamic Equivalence to the Originator

June 15th 2017

By Jackie Syrop

The study pesented at the American Diabetes Association 77th Scientific Sessions compared Mylan/Biocon’s MYL-1501D, a proposed biosimilar to Sanofi-Aventis’ insulin glargine, with the reference product.

Study Finds Significant Differences in Glycemic Control Between Reference and Biosimilar Morning Insulin

June 14th 2017

By Kelly Davio

In order to investigate the best morning insulin therapy to improve glycemic variability in patients with type 2 diabetes, researchers from Japan compared morning injections of insulin glulisine and insulin glargine with injections of insulin lispro and insulin glargine biosimilar.

New Bill in Nevada Spotlights Ambiguity in Insulin Pricing

May 24th 2017

By Jackie Syrop

EMA Recommends Approval of Sanofi's Insulin Lispro Biosimilar

May 22nd 2017

By Jackie Syrop